Author: mattstrongalldaylong

The METTSEO trial is a new Phase 1 clinical study sponsored by the Moffitt Cancer Center for patients newly diagnosed

Patients fighting Ewing sarcoma often respond well to their first round of treatment. However, if the cancer returns (relapses) or

Because childhood cancers are rare, finding funding and developing new treatments for them is incredibly difficult; in fact, the standard

Childhood cancer survivors face a higher risk of developing serious long-term health issues such as heart disease and other cancers

Researchers at the University of Birmingham discovered a new genetic indicator, called a “biomarker,” that can predict which children with

Doctors are using a advanced tool called “genomic tumor profiling” to better understand and treat rare muscle and bone cancers

An article titled “Baseline ¹⁸F-FDG PET/CT-Derived SUVmin and Metabolic Heterogeneity as Predictors of Survival and Metastasis in Bone Sarcomas,” explores